Cargando…

ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling

BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Lian-Jing, Zhang, Yi-Jun, Dong, Si-Qi, Li, Xi-Zhao, Tong, Xia-Ting, Chen, Dong, Wu, Zi-Yi, Zheng, Xiao-Hui, Xue, Wen-Qiong, Jia, Wei-Hua, Zhang, Jiang-Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986551/
https://www.ncbi.nlm.nih.gov/pubmed/33757572
http://dx.doi.org/10.1186/s13046-021-01905-x
_version_ 1783668468179009536
author Cao, Lian-Jing
Zhang, Yi-Jun
Dong, Si-Qi
Li, Xi-Zhao
Tong, Xia-Ting
Chen, Dong
Wu, Zi-Yi
Zheng, Xiao-Hui
Xue, Wen-Qiong
Jia, Wei-Hua
Zhang, Jiang-Bo
author_facet Cao, Lian-Jing
Zhang, Yi-Jun
Dong, Si-Qi
Li, Xi-Zhao
Tong, Xia-Ting
Chen, Dong
Wu, Zi-Yi
Zheng, Xiao-Hui
Xue, Wen-Qiong
Jia, Wei-Hua
Zhang, Jiang-Bo
author_sort Cao, Lian-Jing
collection PubMed
description BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD family, the function and molecular mechanism of ATAD2 in cancer development is seldomly investigated. METHODS: The clinical impact of ATAD2 was assessed both at RNA and protein level in 75 and 112 ESCC patients separately. The biological function of ATAD2 was investigated in vitro and in vivo. Signaling pathway and downstream effectors of ATAD2 were identified by RNA sequencing, luciferase reporter, co-immunoprecipitation, chromatin immunoprecipitation, immunofluorescence and western blot assay. RESULTS: We found that elevated ATAD2 expression was significantly associated with lymph node metastasis, advanced clinical stage as well as poor survival of ESCC patients. Silencing ATAD2 significantly suppressed ESCC cell migration and invasion in vitro, and inhibited tumor growth and lung metastasis in vivo. Mechanically, we identified a new cofactor, C/EBPβ. ATAD2 directly interacted with C/EBPβ and promoted its nuclear translocation, which directly bound to the promoter region of TGF-β1 and activated its expression. Further, we demonstrated that TGF-β1 activated its downstream effectors in a Smad3 dependent manner. In addition, we further found that ATAD2 promoted ESCC metastasis through TGF-β signaling induced Snail expression and the subsequent epithelial-mesenchymal transition. CONCLUSION: Our findings demonstrated the pro-metastatic function of ATAD2 and uncovered the new molecular mechanism by regulating C/EBPβ/TGF-β1/Smad3/Snail signaling pathway, thus providing a potential target for the treatment of ESCC metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01905-x.
format Online
Article
Text
id pubmed-7986551
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79865512021-03-25 ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling Cao, Lian-Jing Zhang, Yi-Jun Dong, Si-Qi Li, Xi-Zhao Tong, Xia-Ting Chen, Dong Wu, Zi-Yi Zheng, Xiao-Hui Xue, Wen-Qiong Jia, Wei-Hua Zhang, Jiang-Bo J Exp Clin Cancer Res Research BACKGROUND: Distant metastasis is the leading cause of death for esophageal squamous cell carcinoma (ESCC) with limited treatment options and unsatisfactory effectiveness. Bromodomain (BRD) containing proteins are emerging targets for cancer therapy with promising effects. As a unique member of BRD family, the function and molecular mechanism of ATAD2 in cancer development is seldomly investigated. METHODS: The clinical impact of ATAD2 was assessed both at RNA and protein level in 75 and 112 ESCC patients separately. The biological function of ATAD2 was investigated in vitro and in vivo. Signaling pathway and downstream effectors of ATAD2 were identified by RNA sequencing, luciferase reporter, co-immunoprecipitation, chromatin immunoprecipitation, immunofluorescence and western blot assay. RESULTS: We found that elevated ATAD2 expression was significantly associated with lymph node metastasis, advanced clinical stage as well as poor survival of ESCC patients. Silencing ATAD2 significantly suppressed ESCC cell migration and invasion in vitro, and inhibited tumor growth and lung metastasis in vivo. Mechanically, we identified a new cofactor, C/EBPβ. ATAD2 directly interacted with C/EBPβ and promoted its nuclear translocation, which directly bound to the promoter region of TGF-β1 and activated its expression. Further, we demonstrated that TGF-β1 activated its downstream effectors in a Smad3 dependent manner. In addition, we further found that ATAD2 promoted ESCC metastasis through TGF-β signaling induced Snail expression and the subsequent epithelial-mesenchymal transition. CONCLUSION: Our findings demonstrated the pro-metastatic function of ATAD2 and uncovered the new molecular mechanism by regulating C/EBPβ/TGF-β1/Smad3/Snail signaling pathway, thus providing a potential target for the treatment of ESCC metastasis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01905-x. BioMed Central 2021-03-23 /pmc/articles/PMC7986551/ /pubmed/33757572 http://dx.doi.org/10.1186/s13046-021-01905-x Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Cao, Lian-Jing
Zhang, Yi-Jun
Dong, Si-Qi
Li, Xi-Zhao
Tong, Xia-Ting
Chen, Dong
Wu, Zi-Yi
Zheng, Xiao-Hui
Xue, Wen-Qiong
Jia, Wei-Hua
Zhang, Jiang-Bo
ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
title ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
title_full ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
title_fullStr ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
title_full_unstemmed ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
title_short ATAD2 interacts with C/EBPβ to promote esophageal squamous cell carcinoma metastasis via TGF-β1/Smad3 signaling
title_sort atad2 interacts with c/ebpβ to promote esophageal squamous cell carcinoma metastasis via tgf-β1/smad3 signaling
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7986551/
https://www.ncbi.nlm.nih.gov/pubmed/33757572
http://dx.doi.org/10.1186/s13046-021-01905-x
work_keys_str_mv AT caolianjing atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT zhangyijun atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT dongsiqi atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT lixizhao atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT tongxiating atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT chendong atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT wuziyi atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT zhengxiaohui atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT xuewenqiong atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT jiaweihua atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling
AT zhangjiangbo atad2interactswithcebpbtopromoteesophagealsquamouscellcarcinomametastasisviatgfb1smad3signaling